Compare SRTA & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRTA | FBRX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | 601 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.3M | 487.2M |
| IPO Year | N/A | 2017 |
| Metric | SRTA | FBRX |
|---|---|---|
| Price | $5.53 | $24.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $7.81 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 741.8K | 349.0K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $39.27 | N/A |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | $9.88 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.85 | $7.00 |
| 52 Week High | $6.02 | $35.80 |
| Indicator | SRTA | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 69.70 | 37.61 |
| Support Level | $4.08 | $22.33 |
| Resistance Level | $5.99 | $34.44 |
| Average True Range (ATR) | 0.30 | 2.17 |
| MACD | 0.06 | -0.55 |
| Stochastic Oscillator | 93.89 | 4.45 |
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.